Facebook Pixel Asia Pacific region is beginning to endorse stem cell treatments | BioSpectrum Asia - Business - Lees dit verhaal op Magzter.com

Poging GOUD - Vrij

Asia Pacific region is beginning to endorse stem cell treatments

BioSpectrum Asia

|

December 2019

Transfiguring the face of medicine, Advancells was established in the year 2013.

- Narayan Kulkarni

Asia Pacific region is beginning to endorse stem cell treatments

Delving in the field of stem cell therapies, the company has been futuristically conceptualized to further modern medicine. Headquartered in Noida it has representative offices in Bangladesh and Australia. Breaking the stereotype regarding stem cell companies that most often offer arrangements for stem cell banking, this is one of the few organisations in India that focuses the therapeutic usage of stem cells for a variety of life threatening and life style diseases. It also works on writing protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. Advancells is a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. It also intends to file a patent for this processing technology in the near future. The company is also associated with “Champions of Change – Transforming India through G2B partnership” initiative of Government of India.

The company maintains superlative scientific and ethical traditions through & Good Manufacturing Practices & assessment of a case followed by the explanation of protocol, risks and rewards to the patient in detail.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Malaysia, Thailand implement medical device reliance programme after successful pilot

The Medical Device Authority (MDA) of Malaysia and the Thai Food and Drug Administration (Thai FDA) signed a Confidentiality Agreement to deepen regulatory cooperation and officially launched a 3-month pilot of the Medical Device Regulatory Reliance Programme as part of the agreement.

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

BioSpectrum Asia

Strand Life Sciences launches South Asia's first Olink Explore HT Proteomics Service

India-based Strand Life Sciences, a subsidiary of Reliance Industries Limited, has announced the launch of its advanced proteomics capabilities powered by Olink Explore HT, marking a key milestone in expanding largescale multi-omics research in South Asia.

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

UK transforms mental healthcare with new strategy

Frontline workers, clinicians and mental health experts are being invited to share their views on how to transform mental healthcare for children and adults in England, as the government launches a call for evidence to shape its once-in-a-generation crossgovernment mental health strategy.

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

Australia Budget 2026-27: Investing in Care, Health and Innovation.

The Australian Federal Budget 2026-27, presented by the Albanese Government, places strong emphasis on healthcare, aged care, T disability services, research, innovation and social equality.

time to read

4 mins

BioSpectrum Asia June 2026

BioSpectrum Asia

BioSpectrum Asia

Gavi proposes new incentives for advancing vaccine manufacturing in Africa

With Gavi's African Vaccine Manufacturing Accelerator (AVMA) expected to make its first cash disbursement to an African vaccine manufacturer in the second half of 2026, Gavi, the Vaccine Alliance has proposed further measures totaling $189 million of additional investment to further aid development of Africa's vaccine manufacturing sector.

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

BioSpectrum Asia

New WHO online course strengthens good practices in clinical trials

High-quality clinical trials are essential for generating reliable evidence to inform health policy, clinical practice and public trust in science.

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

BioSpectrum Asia

World Bank approves $225 M to improve healthcare in Côte d'Ivoire

The World Bank has approved $225 million in financing to help Côte d'Ivoire improve the delivery of quality health, nutrition, and early childhood development services for millions of people, particularly for women, children, and vulnerable households.

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

BioSpectrum Asia

Nona Biosciences appoints Dr Josh Xiao as CSO

Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, has announced the appointment of Dr Josh Xiao as Chief Scientific Officer (CSO). Dr Xiao will be based in both the US and China and report directly to Dr Di Hong, Chief Executive Officer of Nona Biosciences.

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

BioSpectrum Asia

Korea lays focus on stabilising medical product supply

The Ministry of Health and Welfare (MoHW), South Korea government, recently held its 7th meeting with healthcare and pharmaceutical associations, bringing together the Ministry of Trade, Industry and Resources (MOTIR), and the Ministry of Food and Drug Safety (MFDS).

time to read

1 min

BioSpectrum Asia June 2026

BioSpectrum Asia

BioSpectrum Asia

Formosa Pharma partners with SERI to advance novel ophthalmic formulations for corneal diseases

Taiwan-based Formosa Pharmaceuticals, Inc. and the Singapore Eye Research Institute (SERI) have announced a strategic research collaboration to develop next-generation ophthalmic formulations.

time to read

1 min

BioSpectrum Asia June 2026

Translate

Share

-
+

Change font size